Efficacy and safety of peri-partum Esketamine for prevention of post-partum depression in women undergoing caesarian section: A meta-analysis and systematic review of randomized controlled trials.
Asian journal of psychiatry July 1, 2024 Muhammad Anas Nayyer, Suchna Meeral Khan, Mohammad Umer et al. 14 citations
A meta-analysis of seven randomized controlled trials examined whether esketamine given around childbirth can prevent postpartum depression (PPD). The analysis found a lower incidence of PPD in women who received esketamine compared to a control group, both in the first week (risk ratio 0.37) and at 4–6 weeks postpartum (risk ratio 0.48). Edinburgh Postnatal Depression Scale scores were significantly lower in the esketamine group during the first week (mean difference -1.23) but not after 4 weeks (mean difference -0.10). Hallucination was significantly more common with esketamine (risk ratio 13.85), while other side effects like dizziness, nausea, and headache did not differ significantly.